Anavex Life Sciences Gets FDA OK for Clinical Study of Genetic Disorder Treatment
Dow Jones10-16
Anavex Life Sciences will proceed with a clinical study of a new drug to treat the genetic disorder Fragile X syndrome after getting clearance from U.S. regulators.
The company said the Food and Drug Administration cleared the study under an investigational new drug application for Anavex 2-73, known generically as blarcamesine.
The drug had previously been named an orphan drug by the FDA.
"FDA clearance of the Fragile X IND is an important milestone that gives Anavex open INDs in all three of our core indications: Alzheimer's Disease, Rett syndrome, and Fragile X syndrome, and supports our continued momentum of working closely with the FDA as we move our programs forward," interim Chief Executive Terrie Kellmeyer said.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments